# Roivant Sciences Ltd.

Summary updated: 2026-10-02T11:21:11.768615Z
Canonical: https://finbar.com/research/companies/roivant-sciences-ltd

## Overview

Roivant Sciences Ltd. is a biopharmaceutical company that develops and commercializes medicines through focused subsidiary companies called “Vants.” It also incubates discovery-stage companies and health-technology startups that complement its biopharmaceutical business. Roivant describes its mission as improving patients’ lives by accelerating the development and commercialization of medicines that matter. [1](https://app.finbar.com/go?id=P119912468) The company was founded in 2014. [2](https://www.roivant.com/about/company)

Its business is defined by developing a portfolio of medicines, including candidates for autoimmune and pulmonary diseases. Roivant’s listed office locations are New York City and Basel, Switzerland. [3](https://www.roivant.com/contact) For the fiscal year ended March 31, 2026, it reported revenue of $8.3 million, primarily from Genevant license agreements. [4](https://app.finbar.com/go?id=P75136564)
[1](https://app.finbar.com/go?id=P119912468)[2](https://www.roivant.com/about/company)[3](https://www.roivant.com/contact)[4](https://app.finbar.com/go?id=P75136564)[2](https://www.roivant.com/about/company)[3](https://www.roivant.com/contact)

## Products & services

Roivant’s marketed product is LISRAYA™ (brepocitinib), an oral, once-daily JAK1/TYK2 inhibitor approved in the U.S. for adults with dermatomyositis [5](https://investor.roivant.com/news-releases/news-release-details/roivant-announces-fda-approval-lisrayatm-brepocitinib-adults). Brepocitinib is also being developed for non-infectious uveitis, cutaneous sarcoidosis, and lichen planopilaris; a Phase 3 non-infectious uveitis study has been initiated [6](https://www.roivant.com/pipeline)[7](https://investor.roivant.com/news-releases/news-release-details/priovant-announces-first-patients-enrolled-phase-3-study-beacon).

Other named clinical-stage products include IMVT-1402, a fully human anti-FcRn monoclonal antibody being studied for autoimmune diseases including rheumatoid arthritis, Graves’ disease, myasthenia gravis, CIDP, and Sjögren’s disease [6](https://www.roivant.com/pipeline). In an early study, weekly 600 mg dosing reduced mean total IgG by 74% after four doses; development for cutaneous lupus erythematosus was later discontinued after the proof-of-concept study missed its primary endpoint [8](https://app.finbar.com/go?id=P93845906)[9](https://app.finbar.com/go?id=P117179771)[10](https://investor.roivant.com/news-releases/news-release-details/roivant-announces-topline-results-proof-concept-study-imvt-1402/). Mosliciguat is an inhaled soluble guanylate cyclase activator in development for pulmonary hypertension associated with interstitial lung disease; its Phase 2 study reported a 56.3% reduction in pulmonary vascular resistance versus placebo at Week 16, and Phase 3 development was underway [11](https://app.finbar.com/go?id=P87408662)[12](https://investor.roivant.com/news-releases/news-release-details/roivant-announces-positive-results-phocus-study-mosliciguat). Company disclosures describe drug discovery capabilities including quantitative proteomics, induced proximity, and covalency; they do not identify a separate external service offering [13](https://app.finbar.com/go?id=P120865333).
[8](https://app.finbar.com/go?id=P93845906)[9](https://app.finbar.com/go?id=P117179771)[11](https://app.finbar.com/go?id=P87408662)[13](https://app.finbar.com/go?id=P120865333)[5](https://investor.roivant.com/news-releases/news-release-details/roivant-announces-fda-approval-lisrayatm-brepocitinib-adults)[6](https://www.roivant.com/pipeline)[7](https://investor.roivant.com/news-releases/news-release-details/priovant-announces-first-patients-enrolled-phase-3-study-beacon)[10](https://investor.roivant.com/news-releases/news-release-details/roivant-announces-topline-results-proof-concept-study-imvt-1402/)[12](https://investor.roivant.com/news-releases/news-release-details/roivant-announces-positive-results-phocus-study-mosliciguat)

## Geographic presence

Roivant lists its principal executive-office address in London, UK, and maintains offices in New York and Basel, Switzerland [14](https://app.finbar.com/go?id=P69922249)[15](https://app.finbar.com/go?id=T7785279)[3](https://www.roivant.com/contact). Its subsidiary Roivant Sciences, Inc. leases 54,702 square feet at One Penn Plaza in New York for the U.S. corporate headquarters; Roivant reports that it owns no properties [16](https://app.finbar.com/go?id=P36265381)[17](https://app.finbar.com/go?id=P67689052).

The company states that its employees and operations are primarily located in the United States [18](https://app.finbar.com/go?id=P58904244). Its clinical development includes a global, multicenter Phase 2 trial [19](https://app.finbar.com/go?id=P123275700). Roivant does not disclose revenue by country or region, or an employee headcount by geography, in the cited FY2026 materials [20](https://app.finbar.com/go?id=P28973557).
[14](https://app.finbar.com/go?id=P69922249)[15](https://app.finbar.com/go?id=T7785279)[16](https://app.finbar.com/go?id=P36265381)[17](https://app.finbar.com/go?id=P67689052)[18](https://app.finbar.com/go?id=P58904244)[19](https://app.finbar.com/go?id=P123275700)[20](https://app.finbar.com/go?id=P28973557)[3](https://www.roivant.com/contact)

## Business segments

Roivant Sciences Ltd. reports one operating and reportable segment: the discovery, development and commercialization of medicines and technologies. Its CEO is the chief operating decision maker; the company does not report separate GAAP segments by Vant, therapeutic area, or product. [21](https://app.finbar.com/go?id=P4555074)[20](https://app.finbar.com/go?id=P28973557)

For the year ended March 31, 2026, the sole reportable segment accounted for all reported consolidated revenue: $8.260 million, or 100% of segment revenue. Roivant describes its Vants as independently managed biotech companies with their own missions and product candidates, but does not disclose their individual revenue contributions as reportable segments. [22](https://app.finbar.com/go?id=T10005737)[23](https://app.finbar.com/go?id=P44648594)[21](https://app.finbar.com/go?id=P4555074)
[21](https://app.finbar.com/go?id=P4555074)[20](https://app.finbar.com/go?id=P28973557)[22](https://app.finbar.com/go?id=T10005737)[23](https://app.finbar.com/go?id=P44648594)

## Company history

Roivant Sciences was founded on April 7, 2014, by Vivek Ramaswamy. Initially registered as Valor Biotechnology Ltd., it adopted the Roivant name in November 2014 and developed a model of building focused subsidiary biotechnology companies, or “Vants.” [24](https://app.finbar.com/go?id=P53224882)[25](https://app.finbar.com/go?id=P2027040)[26](https://investor.roivant.com/news-releases/news-release-details/roivant-sciences-announces-change-its-board-directors) In 2015, its subsidiary Axovant completed an initial public offering, an early example of the Vant model. [27](https://www.sec.gov/Archives/edgar/data/1636050/000104746915005125/a2224888zs-1a.htm)[28](https://www.prnewswire.com/news-releases/axovant-sciences-ltd-announces-completion-of-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares-300100054.html)

In December 2019, Roivant transferred interests in five Vants—Myovant, Urovant, Enzyvant, Altavant and Spirovant—to Sumitomo Pharma. [29](https://app.finbar.com/go?id=P46673057) A Myovant-developed medicine, relugolix (Orgovyx), was approved by the FDA for advanced prostate cancer in December 2020. [30](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-relugolix-advanced-prostate-cancer) In January 2021, Ramaswamy stepped down as CEO and Matthew Gline took the role; Roivant completed its business combination with Montes Archimedes Acquisition Corp. in September 2021 and began trading on Nasdaq as ROIV. [31](https://app.finbar.com/go?id=P163970924)[26](https://investor.roivant.com/news-releases/news-release-details/roivant-sciences-announces-change-its-board-directors)[32](https://investor.roivant.com/news-releases/news-release-details/roivant-sciences-reports-first-fiscal-quarter-2021-financial) Roivant and Pfizer formed Telavant in 2022 to develop RVT-3101; Roche acquired Telavant in December 2023. [33](https://app.finbar.com/go?id=P5407731)[34](https://app.finbar.com/go?id=P7547005) In October 2024, Organon completed its acquisition of Dermavant. [35](https://app.finbar.com/go?id=P109275729)
[24](https://app.finbar.com/go?id=P53224882)[25](https://app.finbar.com/go?id=P2027040)[29](https://app.finbar.com/go?id=P46673057)[31](https://app.finbar.com/go?id=P163970924)[33](https://app.finbar.com/go?id=P5407731)[34](https://app.finbar.com/go?id=P7547005)[35](https://app.finbar.com/go?id=P109275729)[26](https://investor.roivant.com/news-releases/news-release-details/roivant-sciences-announces-change-its-board-directors)[27](https://www.sec.gov/Archives/edgar/data/1636050/000104746915005125/a2224888zs-1a.htm)[28](https://www.prnewswire.com/news-releases/axovant-sciences-ltd-announces-completion-of-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares-300100054.html)[30](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-relugolix-advanced-prostate-cancer)[32](https://investor.roivant.com/news-releases/news-release-details/roivant-sciences-reports-first-fiscal-quarter-2021-financial)

## Sources

1. [Roivant Sciences Ltd. — Full financial report (2026 Y)](https://app.finbar.com/go?id=P119912468)
2. [www.roivant.com](https://www.roivant.com/about/company)
3. [www.roivant.com](https://www.roivant.com/contact)
4. [Roivant Sciences Ltd. — Full financial report (2026 Y)](https://app.finbar.com/go?id=P75136564)
5. [investor.roivant.com](https://investor.roivant.com/news-releases/news-release-details/roivant-announces-fda-approval-lisrayatm-brepocitinib-adults)
6. [www.roivant.com](https://www.roivant.com/pipeline)
7. [investor.roivant.com](https://investor.roivant.com/news-releases/news-release-details/priovant-announces-first-patients-enrolled-phase-3-study-beacon)
8. [Roivant Sciences Ltd. — Full financial report (2026 Y)](https://app.finbar.com/go?id=P93845906)
9. [Roivant Sciences Ltd. — Full financial report (2026 Y)](https://app.finbar.com/go?id=P117179771)
10. [investor.roivant.com](https://investor.roivant.com/news-releases/news-release-details/roivant-announces-topline-results-proof-concept-study-imvt-1402/)
11. [Roivant Sciences Ltd. — Full financial report (2026 Y)](https://app.finbar.com/go?id=P87408662)
12. [investor.roivant.com](https://investor.roivant.com/news-releases/news-release-details/roivant-announces-positive-results-phocus-study-mosliciguat)
13. [Roivant Sciences Ltd. — Full financial report (2026 Y)](https://app.finbar.com/go?id=P120865333)
14. [Roivant Sciences Ltd. — Full financial report (2026 Y)](https://app.finbar.com/go?id=P69922249)
15. [Roivant Sciences Ltd. — Full financial report (2026 Y)](https://app.finbar.com/go?id=T7785279)
16. [Roivant Sciences Ltd. — Full financial report (2026 Y)](https://app.finbar.com/go?id=P36265381)
17. [Roivant Sciences Ltd. — Full financial report (2026 Y)](https://app.finbar.com/go?id=P67689052)
18. [Roivant Sciences Ltd. — Full financial report (2026 Y)](https://app.finbar.com/go?id=P58904244)
19. [Roivant Sciences Ltd. — Presentation (2026 Y), p26](https://app.finbar.com/go?id=P123275700)
20. [Roivant Sciences Ltd. — Full financial report (2026 Y)](https://app.finbar.com/go?id=P28973557)
21. [Roivant Sciences Ltd. — Full financial report (2026 Y)](https://app.finbar.com/go?id=P4555074)
22. [Roivant Sciences Ltd. — Full financial report (2026 Y)](https://app.finbar.com/go?id=T10005737)
23. [Roivant Sciences Ltd. — Full financial report (2026 Y)](https://app.finbar.com/go?id=P44648594)
24. [Roivant Sciences Ltd. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P53224882)
25. [Roivant Sciences Ltd. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P2027040)
26. [investor.roivant.com](https://investor.roivant.com/news-releases/news-release-details/roivant-sciences-announces-change-its-board-directors)
27. [www.sec.gov](https://www.sec.gov/Archives/edgar/data/1636050/000104746915005125/a2224888zs-1a.htm)
28. [www.prnewswire.com](https://www.prnewswire.com/news-releases/axovant-sciences-ltd-announces-completion-of-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares-300100054.html)
29. [Roivant Sciences Ltd. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P46673057)
30. [www.fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-relugolix-advanced-prostate-cancer)
31. [Roivant Sciences Ltd. — Ipo (2021 O)](https://app.finbar.com/go?id=P163970924)
32. [investor.roivant.com](https://investor.roivant.com/news-releases/news-release-details/roivant-sciences-reports-first-fiscal-quarter-2021-financial)
33. [Roivant Sciences Ltd. — Full financial report (2026 Y)](https://app.finbar.com/go?id=P5407731)
34. [Roivant Sciences Ltd. — Full financial report (2026 Y)](https://app.finbar.com/go?id=P7547005)
35. [Roivant Sciences Ltd. — Full financial report (2026 Y)](https://app.finbar.com/go?id=P109275729)

AI-generated summary; may contain errors. Not investment advice. Sign up to Finbar to view original document sources and access worldwide fundamental financial data and intelligence.